Which has preferable valuation and earnings, RKTO or GNPX?

Rocket One Inc. Common Stock is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rocket One Inc. Common Stock N/A N/A -$12.47M -$0.80 N/A Genprex N/A N/A -$16.23M -$14.14 N/A

Is RKTO or GNPX more profitable?

Rocket One Inc. Common Stock's return on equity of -165.25% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Rocket One Inc. Common Stock N/A -165.25% -143.61% Genprex N/A -247.32% -176.73%

Does the media favor RKTO or GNPX?

In the previous week, Genprex had 1 more articles in the media than Rocket One Inc. Common Stock. MarketBeat recorded 2 mentions for Genprex and 1 mentions for Rocket One Inc. Common Stock. Genprex's average media sentiment score of 0.66 beat Rocket One Inc. Common Stock's score of 0.00 indicating that Genprex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket One Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genprex 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate GNPX or KYNB?

Kyntra Bio has a consensus target price of $30.00, suggesting a potential upside of 347.76%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts plainly believe Kyntra Bio is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better earnings and valuation, GNPX or KYNB?

Kyntra Bio has higher revenue and earnings than Genprex. Genprex is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genprex N/A N/A -$16.23M -$14.14 N/A Kyntra Bio $6.44M 4.21 $183.45M $40.46 0.17

Is GNPX or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Genprex's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Genprex N/A -247.32% -176.73% Kyntra Bio 2,199.13% N/A -36.71%

Do analysts rate GNPX or NNVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher valuation and earnings, GNPX or NNVC?

NanoViricides is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genprex N/A N/A -$16.23M -$14.14 N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is GNPX or NNVC more profitable?

NanoViricides' return on equity of -87.90% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Genprex N/A -247.32% -176.73% NanoViricides N/A -87.90% -78.69%

Does the media refer more to GNPX or NNVC?

In the previous week, NanoViricides had 1 more articles in the media than Genprex. MarketBeat recorded 3 mentions for NanoViricides and 2 mentions for Genprex. Genprex's average media sentiment score of 0.66 beat NanoViricides' score of 0.42 indicating that Genprex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genprex 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NanoViricides 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GNPX or SKYE?

Skye Bioscience has a consensus target price of $9.80, indicating a potential upside of 1,285.55%. Given Skye Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Skye Bioscience is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57

Which has stronger valuation and earnings, GNPX or SKYE?

Skye Bioscience is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genprex N/A N/A -$16.23M -$14.14 N/A Skye Bioscience N/A N/A -$55.92M -$1.44 N/A

Is GNPX or SKYE more profitable?

Skye Bioscience's return on equity of -217.27% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Genprex N/A -247.32% -176.73% Skye Bioscience N/A -217.27% -162.39%

Does the media prefer GNPX or SKYE?

In the previous week, Genprex and Genprex both had 2 articles in the media. Genprex's average media sentiment score of 0.66 beat Skye Bioscience's score of 0.00 indicating that Genprex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genprex 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Skye Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer AIXC or GNPX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, AIXC or GNPX?

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A Genprex N/A N/A -$16.23M -$14.14 N/A

Is AIXC or GNPX more profitable?

Genprex's return on equity of -247.32% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A -771.52% -79.52% Genprex N/A -247.32% -176.73%

Does the media prefer AIXC or GNPX?

In the previous week, Genprex had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for Genprex and 1 mentions for Qualigen Therapeutics. Genprex's average media sentiment score of 0.66 beat Qualigen Therapeutics' score of 0.00 indicating that Genprex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genprex 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Genprex (GNPX) Competitors

$0.58 -0.01 (-1.52%)

Closing price 06/18/2026 03:59 PM Eastern

Extended Trading

$0.57 -0.01 (-1.72%)

As of 06/18/2026 07:58 PM Eastern

Compare

GNPX vs. RKTO, KYNB, NNVC, SKYE, and AIXC

Should you buy Genprex stock or one of its competitors? MarketBeat compares Genprex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genprex include Rocket One Inc. Common Stock (RKTO), Kyntra Bio (KYNB), NanoViricides (NNVC), Skye Bioscience (SKYE), and Qualigen Therapeutics (AIXC). These companies are all part of the "pharmaceutical products" industry.

How does Genprex compare to Rocket One Inc. Common Stock?

Rocket One Inc. Common Stock (NASDAQ:RKTO) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Rocket One Inc. Common Stock is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A

In the previous week, Genprex had 1 more articles in the media than Rocket One Inc. Common Stock. MarketBeat recorded 2 mentions for Genprex and 1 mentions for Rocket One Inc. Common Stock. Genprex's average media sentiment score of 0.66 beat Rocket One Inc. Common Stock's score of 0.00 indicating that Genprex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket One Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genprex	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rocket One Inc. Common Stock has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Genprex has a beta of -0.98, meaning that its share price is 198% less volatile than the broader market.

7.1% of Rocket One Inc. Common Stock shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 6.9% of Rocket One Inc. Common Stock shares are owned by insiders. Comparatively, 0.3% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Rocket One Inc. Common Stock's return on equity of -165.25% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%
Genprex	N/A	-247.32%	-176.73%

Rocket One Inc. Common Stock currently has a consensus price target of $5.00, suggesting a potential upside of 362.96%. Given Rocket One Inc. Common Stock's stronger consensus rating and higher possible upside, research analysts clearly believe Rocket One Inc. Common Stock is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Rocket One Inc. Common Stock beats Genprex on 9 of the 13 factors compared between the two stocks.

How does Genprex compare to Kyntra Bio?

Genprex (NASDAQ:GNPX) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Kyntra Bio has a consensus target price of $30.00, suggesting a potential upside of 347.76%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts plainly believe Kyntra Bio is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Kyntra Bio has a net margin of 2,199.13% compared to Genprex's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-247.32%	-176.73%
Kyntra Bio	2,199.13%	N/A	-36.71%

14.1% of Genprex shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 0.3% of Genprex shares are held by insiders. Comparatively, 4.2% of Kyntra Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kyntra Bio has higher revenue and earnings than Genprex. Genprex is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A
Kyntra Bio	$6.44M	4.21	$183.45M	$40.46	0.17

Genprex has a beta of -0.98, suggesting that its share price is 198% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

In the previous week, Genprex had 2 more articles in the media than Kyntra Bio. MarketBeat recorded 2 mentions for Genprex and 0 mentions for Kyntra Bio. Genprex's average media sentiment score of 0.66 beat Kyntra Bio's score of 0.00 indicating that Genprex is being referred to more favorably in the media.

Company	Overall Sentiment
Genprex	Positive
Kyntra Bio	Neutral

Summary

Kyntra Bio beats Genprex on 14 of the 16 factors compared between the two stocks.

How does Genprex compare to NanoViricides?

Genprex (NASDAQ:GNPX) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

In the previous week, NanoViricides had 1 more articles in the media than Genprex. MarketBeat recorded 3 mentions for NanoViricides and 2 mentions for Genprex. Genprex's average media sentiment score of 0.66 beat NanoViricides' score of 0.42 indicating that Genprex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genprex	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NanoViricides	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NanoViricides is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

NanoViricides' return on equity of -87.90% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-247.32%	-176.73%
NanoViricides	N/A	-87.90%	-78.69%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Genprex has a beta of -0.98, meaning that its share price is 198% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

14.1% of Genprex shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 0.3% of Genprex shares are held by company insiders. Comparatively, 3.6% of NanoViricides shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

NanoViricides beats Genprex on 9 of the 12 factors compared between the two stocks.

How does Genprex compare to Skye Bioscience?

Genprex (NASDAQ:GNPX) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

In the previous week, Genprex and Genprex both had 2 articles in the media. Genprex's average media sentiment score of 0.66 beat Skye Bioscience's score of 0.00 indicating that Genprex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genprex	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Skye Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Skye Bioscience is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

Skye Bioscience has a consensus target price of $9.80, indicating a potential upside of 1,285.55%. Given Skye Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Skye Bioscience is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

14.1% of Genprex shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 0.3% of Genprex shares are owned by company insiders. Comparatively, 6.2% of Skye Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Skye Bioscience's return on equity of -217.27% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-247.32%	-176.73%
Skye Bioscience	N/A	-217.27%	-162.39%

Genprex has a beta of -0.98, suggesting that its share price is 198% less volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.95, suggesting that its share price is 195% more volatile than the broader market.

Summary

Skye Bioscience beats Genprex on 10 of the 13 factors compared between the two stocks.

How does Genprex compare to Qualigen Therapeutics?

Qualigen Therapeutics (NASDAQ:AIXC) and Genprex (NASDAQ:GNPX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 0.3% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Genprex's return on equity of -247.32% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
Genprex	N/A	-247.32%	-176.73%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Genprex had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for Genprex and 1 mentions for Qualigen Therapeutics. Genprex's average media sentiment score of 0.66 beat Qualigen Therapeutics' score of 0.00 indicating that Genprex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genprex	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qualigen Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Genprex has a beta of -0.98, suggesting that its stock price is 198% less volatile than the broader market.

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A

Summary

Genprex beats Qualigen Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Genprex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNPX vs. The Competition

Export

Metric	Genprex	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.47M	$3.41B	$6.43B	$12.60B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-0.04	19.73	24.75	24.44
Price / Sales	N/A	321.37	533.15	110.18
Price / Cash	N/A	127.84	45.07	55.09
Price / Book	0.24	8.16	10.80	6.58
Net Income	-$16.23M	$23.94M	$3.57B	$337.17M
7 Day Performance	-8.93%	2.57%	0.72%	0.83%
1 Month Performance	-28.47%	0.69%	0.41%	2.25%
1 Year Performance	-95.58%	55.09%	29.34%	36.14%

Genprex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNPX Genprex	1.0809 of 5 stars	$0.58 -1.5%	N/A	-95.6%	$6.47M	N/A	N/A	20	News Coverage Gap Down High Trading Volume
RKTO Rocket One Inc. Common Stock	1.566 of 5 stars	$1.30 -12.2%	$5.00 +284.6%	-10.7%	$29.02M	N/A	N/A	4	Gap Up High Trading Volume
KYNB Kyntra Bio	2.6796 of 5 stars	$7.89 +16.7%	$30.00 +280.2%	N/A	$28.63M	$6.44M	0.17	570	Analyst Forecast Gap Up
NNVC NanoViricides	0.64 of 5 stars	$1.30 -5.5%	N/A	-2.1%	$28.03M	N/A	N/A	20	Gap Down
SKYE Skye Bioscience	1.8273 of 5 stars	$0.79 -0.8%	$9.80 +1,135.8%	-67.3%	$27.87M	N/A	N/A	11	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNPX) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genprex (GNPX) Competitors

GNPX vs. RKTO, KYNB, NNVC, SKYE, and AIXC

How does Genprex compare to Rocket One Inc. Common Stock?

Summary

How does Genprex compare to Kyntra Bio?

Summary

How does Genprex compare to NanoViricides?

Summary

How does Genprex compare to Skye Bioscience?

Summary

How does Genprex compare to Qualigen Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX vs. The Competition

Genprex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genprex (GNPX) Competitors

GNPX vs. RKTO, KYNB, NNVC, SKYE, and AIXC

How does Genprex compare to Rocket One Inc. Common Stock?

Which has preferable valuation and earnings, RKTO or GNPX?

Does the media favor RKTO or GNPX?

Which has more risk and volatility, RKTO or GNPX?

Do institutionals & insiders hold more shares of RKTO or GNPX?

Is RKTO or GNPX more profitable?

Do analysts recommend RKTO or GNPX?

Summary

How does Genprex compare to Kyntra Bio?

Do analysts rate GNPX or KYNB?

Is GNPX or KYNB more profitable?

Do insiders & institutionals hold more shares of GNPX or KYNB?

Which has better earnings and valuation, GNPX or KYNB?

Which has more volatility & risk, GNPX or KYNB?

Does the media refer more to GNPX or KYNB?

Summary

How does Genprex compare to NanoViricides?

Does the media refer more to GNPX or NNVC?

Which has higher valuation and earnings, GNPX or NNVC?

Is GNPX or NNVC more profitable?

Do analysts rate GNPX or NNVC?

Which has more risk and volatility, GNPX or NNVC?

Do insiders and institutionals hold more shares of GNPX or NNVC?

Summary

How does Genprex compare to Skye Bioscience?

Does the media prefer GNPX or SKYE?

Which has stronger valuation and earnings, GNPX or SKYE?

Do analysts prefer GNPX or SKYE?

Do institutionals & insiders believe in GNPX or SKYE?

Is GNPX or SKYE more profitable?

Which has more risk and volatility, GNPX or SKYE?

Summary

How does Genprex compare to Qualigen Therapeutics?

Do institutionals and insiders believe in AIXC or GNPX?

Is AIXC or GNPX more profitable?

Do analysts prefer AIXC or GNPX?

Does the media prefer AIXC or GNPX?

Which has more volatility and risk, AIXC or GNPX?

Which has better earnings & valuation, AIXC or GNPX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX vs. The Competition

Genprex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools